

## BARHEMSYS - (5MG/2ML, 10MG/4ML ; Solution)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | AMISULPRIDE  | <b>Innovator</b>            | Acacia              |
| <b>Dosage</b>                | 5MG/2ML, 10MG/4ML ; Solution   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None   | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | None   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | BARHEMSYS is a dopamine-2 (D2) antagonist indicated in adults for: • Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. • Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.